Singapore, May 21 -- To focus on digitising cell manufacturing processes through robotics technology.

Astellas Pharma Inc. has signed a Memorandum of Understanding (MoU) with Yaskawa Electric Corporation to begin discussions on the creation of an innovative cell therapy ecosystem through the integration of pharmaceutical and robotics technologies. This MoU is legally non-binding and will lead to further specific discussions between the two companies in the future.

The complexity of product manufacturing is a significant challenge to commercialising cell therapy. Substantial investments are required to develop complex manufacturing processes, transfer technology among manufacturers, and establish large-scale manufacturing facilities for ...